25.41 USD
-0.05 (-0.2%)
25.41 USD
0 (0%)
Overall BLFS gets a fundamental rating of 5 out of 10. We evaluated BLFS against 57 industry peers in the Life Sciences Tools & Services industry. While BLFS has a great health rating, there are worries on its profitability. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLFS had positive earnings in the past year.
In the past year BLFS had a positive cash flow from operations.
In the past 5 years BLFS reported 4 times negative net income.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
1.2 Ratios
BLFS has a Return On Assets of -0.82%. This is comparable to the rest of the industry: BLFS outperforms 59.65% of its industry peers.
With a decent Return On Equity value of -0.91%, BLFS is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLFS has a better Gross Margin (70.02%) than 92.98% of its industry peers.
BLFS's Gross Margin has been stable in the last couple of years.
BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLFS has more shares outstanding
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
The debt/assets ratio for BLFS has been reduced compared to a year ago.
2.2 Solvency
BLFS has an Altman-Z score of 18.42. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 18.42, BLFS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for BLFS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.42 |
ROIC/WACCN/A
WACC10.86%
2.3 Liquidity
A Current Ratio of 4.66 indicates that BLFS has no problem at all paying its short term obligations.
BLFS has a Current ratio of 4.66. This is in the better half of the industry: BLFS outperforms 75.44% of its industry peers.
BLFS has a Quick Ratio of 3.64. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BLFS (3.64) is better than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.36%, which is quite impressive.
The Revenue for BLFS has decreased by -24.98% in the past year. This is quite bad
Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
3.2 Future
The Earnings Per Share is expected to grow by 29.91% on average over the next years. This is a very strong growth
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.63% yearly.
EPS Next Y32.33%
EPS Next 2Y47.08%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue Next Year-9.14%
Revenue Next 2Y1.83%
Revenue Next 3Y8.38%
Revenue Next 5Y15.63%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BLFS is valuated quite expensively with a Price/Earnings ratio of 101.64.
BLFS's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.59, BLFS is valued quite expensively.
With a Price/Forward Earnings ratio of 305.03, BLFS can be considered very expensive at the moment.
BLFS's Price/Forward Earnings is on the same level as the industry average.
BLFS is valuated expensively when we compare the Price/Forward Earnings ratio to 24.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101.64 | ||
| Fwd PE | 305.03 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as BLFS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 231.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 40.10% in the coming years.
PEG (NY)3.14
PEG (5Y)N/A
EPS Next 2Y47.08%
EPS Next 3Y40.1%
5. Dividend
5.1 Amount
No dividends for BLFS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
25.41
-0.05 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners103.58%
Inst Owner Change-2.65%
Ins Owners2.07%
Ins Owner Change-1.39%
Market Cap1.22B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price TargetN/A
Short Float %6.19%
Short Ratio8.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)2.56%
PT rev (3m)2.56%
EPS NQ rev (1m)-60%
EPS NQ rev (3m)-199.85%
EPS NY rev (1m)6.02%
EPS NY rev (3m)-16.09%
Revenue NQ rev (1m)-2.27%
Revenue NQ rev (3m)-9.5%
Revenue NY rev (1m)-3.96%
Revenue NY rev (3m)-4.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 101.64 | ||
| Fwd PE | 305.03 | ||
| P/S | 13.77 | ||
| P/FCF | N/A | ||
| P/OCF | 72.64 | ||
| P/B | 3.46 | ||
| P/tB | 9.13 | ||
| EV/EBITDA | 231.53 |
EPS(TTM)0.25
EY0.98%
EPS(NY)0.08
Fwd EY0.33%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.38%
SpS1.84
BVpS7.35
TBVpS2.78
PEG (NY)3.14
PEG (5Y)N/A
Graham Number6.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% | ||
| FCFM | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 298.5% | ||
| Cap/Sales | 19.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 353.72% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 18.42 |
F-Score6
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y32.33%
EPS Next 2Y47.08%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-9.14%
Revenue Next 2Y1.83%
Revenue Next 3Y8.38%
Revenue Next 5Y15.63%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year325.11%
EBIT Next 3Y89.24%
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BLFS.
What is the valuation status for BLFS stock?
ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.
Can you provide the profitability details for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.
What is the financial health of BIOLIFE SOLUTIONS INC (BLFS) stock?
The financial health rating of BIOLIFE SOLUTIONS INC (BLFS) is 8 / 10.
Can you provide the dividend sustainability for BLFS stock?
The dividend rating of BIOLIFE SOLUTIONS INC (BLFS) is 0 / 10 and the dividend payout ratio is 0%.